Clinical trial comparing the sedative effect of Dexmedetomidin infusion versus placebo in the intensive care unit on patients undergoing open heart surgery under cardiopulmonary bypass pump.

compare the efficacy of sedative effect of Dexmedetomidin infusion with placebo in patients undergoing open heart surgery in the intensive care unit

In this double blind clinical trial, 60 patients undergoing open heart surgery under a cardiopulmonary bypass pump, were randomly assigned into two groups of Dexmedetomidine and placebo

In this double blind clinical trial, 60 patients undergoing open heart surgery under a cardiopulmonary bypass pump, who were referred to Baqiyatallah Hospital, were randomly assigned randomly into two groups of Dexmedetomidine (group D) and placebo (group P). The medication is prepared by a collaborator, and the investigator and the patient will not be aware of the type of injectable drug.

60 patients undergoing open heart surgery are studied. Emergency patients, patients with liver and renal failure, grade 2 or 3 cardiac block, history of psychiatric disorders, drug addicts and redu surgery are not included in the study.

In the dexmedmotidine group after completing the operation, doses of dexmedetomidine 1μg/ kg infused over 10 minutes and transferred to the ICU and placed under mechanical ventilation. In ICU, low dose infused doses of 0.2 μg / kg will increase, and the dose will increase to 0.7 μg / kg. In placebo group, normal saline is infused within 10 minutes and transferred to ICU and placed under mechanical ventilation. In ICU, placebo infusion continues. In the two groups, the purpose of sedation is until the patient is mechanically ventilated by Richmond agitation sedation scale ( RASS) -2_ + 1 and after extubation of RASS 0.

Reduced Delirium, duration of stay in ICU, duration of mechanical ventilation, Dose of midazolam and morphine, incidence of arrhythmia and Increased satisfaction of nurses in the intensive care unit

Randomization was stratified using a random table number

The medication or placebo is prepared and coded by the co-worker in a 50cc syringe. Each cc of the solution in the syringe contains four micrograms of Dexmedetomidine or a placebo. The patient and the researcher and the specialist nurses will not be informed of the prepared syringe's contents. Researcher will be injected into a patient for 10 minutes from a randomized encoded syringe, equivalent to 1 μg / kg Dexmedetomidine and then the medicine will be infused In a volume equivalent to 0.2 to 0.7 micrograms per kilogram, in accordance with the patient's needs. Upon completion of the sampling, the co-worker will provide the information about the coding of the syringes.

all collected deidentified IPD

starting 1 months after publication

people working in academic institutions

for meta analysis

from Email

By sending a request to the university Vice-Dean for Research and obtaining a license